Home » Health » CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective conscientiously but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past few shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a highly marketing image in the Uptick Newswire employment interview which I came away with a poor viewpoint of the business.

Irony of irony, my bad impression of the company has grown steadily, though the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this know-how as well as associated intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) plus the first new drug program endorsement ($five million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it’s this single treatment as well as a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active business with diverse interests albeit focused on leronlimab, several disease types, multiple publications in addition to multiple presentations.

Can all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very start of the interest of mine in this particular company. Judging by way of the multiples of thousands of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News